Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing |
| |
Authors: | Tep Samnang Mihaila Radu Freeman Alexander Pickering Victoria Huyhn Felicia Tadin-Strapps Marija Stracks Allison Hubbard Brian Caldwell Jeremy Flanagan W Michael Kuklin Nelly A Ason Brandon |
| |
Affiliation: | Sirna Therapeutics/Merck & Co. Inc., San Francisco, CA 94158, USA. samnang.tep@gmail.com |
| |
Abstract: | Microsomal triglyceride transfer protein (Mtp) inhibitors represent a novel therapeutic approach to lower circulating LDL cholesterol, although therapeutic development has been hindered by the observed increase in hepatic triglycerides and liver steatosis following treatment. Here, we used small interfering RNAs (siRNA) targeting Mtp to achieve target-specific silencing to study this phenomenon and to determine to what extent liver steatosis is induced by changes in Mtp expression. We observed that Mtp silencing led to a decrease in many genes involved in hepatic triglyceride synthesis. Given the role of diacylglycerol O-acyltransferase 2 (Dgat2) in regulating hepatic triglyceride synthesis, we then evaluated whether target-specific silencing of both Dgat2 and Mtp were sufficient to attenuate Mtp silencing-induced liver steatosis. We showed that the simultaneous inhibition of Dgat2 and Mtp led to a decrease in plasma cholesterol and a reduction in the accumulation of hepatic triglycerides caused by the inhibition of Mtp. Collectively, these findings provide a proof-of-principle for a triglyceride synthesis/Mtp inhibitor combination and represent a potentially novel approach for therapeutic development in which targeting multiple pathways can achieve the desired response. |
| |
Keywords: | RNAi combination therapies low density lipoprotein cholesterol dyslipidemia atherosclerosis |
本文献已被 ScienceDirect PubMed 等数据库收录! |